ABSTRACT
A topic eczema, chronic urticaria, generalized chronic pruritus, and other chronic allergic-like dermatitis syndromes very often are defined as "idiopathic," because in most cases it is not possible to find a clear-cut aetiopathogenetic cause. The term "allergiclike" disease is often used to classify and put together different diseases quite similar to the allergic ones, with which they can share the same underlying immunologic mechanisms, but for which an allergic sensitization and a true allergic (IgE-mediated) pathogenesis cannot be proved.
A small number of clinical and experimental studies suggest that dietary nickel could be the possible cause for the provocation and persistence of symptoms in some patients with concomitant nickel sensitization. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Nickel-sensitized patients, when exposed to the hapten given per os, can develop a flare-up reaction of previous contact dermatitis. Systemic contact dermatitis (SCD) is the term normally used to describe clinical manifestations of the systemic provocation by nickel and some other haptens. [12] [13] [14] [15] The flare-up of healing or quiescent contact dermatitis is the most frequent reaction, but pompholix, dyshidrosic or vescicular eczema, toxicoderma-like rash, chronic pruritus, maculo-papular rash, vasculitis-like lesions, flexural dermatitis, papuloerythroderma-like eruptions, chronic urticaria, pseudo-atopic dermatitis, generalized rash, and baboon syndrome are several clinical variants within the spectrum of systemically induced allergic contact dermatitis (ACD).
1-21 SCD should be considered as an "umbrella term," which includes a broad spectrum of clinical manifestations that can occur when a person sensitized to a contact allergen is exposed to the same allergen through a systemic route.
Data in medical literature about systemically induced nickel dermatitis present some inconsistencies related to diagnostic procedures, diet, and doses of challenge and do not allow to draw definitive conclusions about the true significance of the syndrome in clinical practice. As a matter of fact, most data have been obtained by experimental procedures of challenge in patients with ACD, and little information exists about the role of dietary nickel in patients with allergiclike dermatitis syndromes.
With the present retrospective study, we have tried to ascertain the clinical and epidemiologic relevance of nickel sensitization in patients with allergic-like skin diseases and the possible impact of dietary nickel on symptoms provocation and persistence.
METHODS

Selection and Inclusion Criteria
We performed a retrospective study on a case series of patients referred to our allergy unit from January 1, 2000 to December 31, 2010 because of chronic skin diseases, compatible with allergic skin disorders for their clinical and morphologic features. These include:
-chronic urticarious skin eruptions -skin lesions suggesting adult atopic eczema (localized variants excluded) -generalized chronic pruritus with or without lesions resulting from scratching -scattered, pruriginous eczemas compatible with allergic skin disorders because of their clinical features (erythematous or erythematous-squamous, blurred-edged patches with more or less evident lichenification) All the cases considered for the present study have been reviewed based on the allergy unit and (as far as the nickel challenge procedure concerns) the day-hospital clinical records. The diagnostic procedures below described have not changed during the whole period of the study.
For the purpose of the present study, urticarious skin manifestations were described as chronic if symptoms persisted for at least two months. In all the other cases, the patients were selected if the symptoms persisted for at least four months.
The allergic, IgE-mediated pathogenesis of skin disorders was excluded based on the next criteria:
-no personal case history of atopy -negative skin tests with commercial extracts of more common pollen and inhalant allergens and a large array of food (including but not limited to those listed below) -negative IgE against the next food allergens: milk, egg, codfish, wheat, natural yeast, tomato, peanuts, soybean, walnuts, and peach and for any other allergens suspected of a possible etiologic role based on case history data When required, specific elimination diet and open challenge was used to exclude foods reported as suspected. Positive results of the open provocation test were further checked by double-blind placebo-controlled food challenge.
A similar procedure has been followed for drugs potentially related to clinical manifestations.
The search for parasites in the feces, special hematochemical, cultural, and/or instrumental tests were performed in a number of cases (notably cases of chronic urticaria and generalized pruritus) to exclude diseases (for instance autoimmune disorders) possibly related to skin manifestations.
Patch tests were performed in all patients using a standard series of haptens, listed by the Italian Group for the Research for Contact Allergic Dermatitis. Patch test results were given according to grading patch test criteria, established by International Contact Dermatitis Research Group guidelines. The subjects with nickelpositive test were given suitable instructions to avoid any possible sources of allergic contact.
The role of contact allergens other than nickel to which the patients could be sensitized was preliminarily ruled out. Patients were instructed to avoid contact exposure, and for haptens that could be cause of SCDs, appropriate avoidance diet was prescribed. Cobalt avoidance diet has not been considered, because cobalt is in general seen as mere nickel cosensitization and dietary suggestions overlap nickel by a large extent. 13, 15, 22 
Low-Nickel Diet
When any possible role of a contact exposure, either professional or extraprofessional, was excluded with certainty, they were prescribed a low-nickel content diet [23] [24] [25] [26] [27] [28] for a period of two to four weeks ( Table 1 ). The regular use of antihistamines and steroids was suspended at the beginning of the diet, allowing the use of antihistamines on demand only for the first days. In particular, if the subject was obliged to resort to antihistaminic or other antiallergic drugs after the first 10 -12 days of dieting, the diet was regarded as ineffective and the role of dietary nickel in the provocation of symptoms was definitively excluded.
Symptoms Score
The trend of subjective symptoms was obtained with a diary based on arbitrary score filled by the patient according to the severity and duration of the manifestations (0: none; 1: mild, tolerable also without regular use of drugs; 2: moderate, acceptable control by therapy; and 3: severe, poor controlled, interfering with ordinary activities and sleep).
The evolution and the extension of skin lesions were controlled based on the score derived from the skin maps, based on Rule of Nine's, Scoring Atopic Dermatitis or Atopic Dermatitis Area and Severity Index system, filled at the first and the last week of the diet.
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Nickel Challenge Test
The patients who showed healing or evident improvement of cutaneous lesions, no less than 60% of skin map initial score, and the patients with chronic pruritus without cutaneous manifestations with stable lowering of at least one step of the subjective symptom score, always adhering to the prescribed diet, underwent an oral, double-blind placebo-controlled nickel challenge (DBPCNC).
In previous studies, the nickel challenge test (up to a dose of 20 mg) proved highly specific, because it resulted ineffective in healthy subjects and in patients with hand eczema or allergic-like dermatitis syndromes not sensitized to nickel. 8, 32, 33 The DBPCNC test was performed in day-hospital regimen with the next, noncumulative doses of 0.5, 1, 5, 10, and 20 mg of nickel sulfate hexahydrate, respectively, equal to 0.11, 0.22, 1.11, 2.23, and 4.47 mg of elemental nickel. Three capsules of p were interpolated at random into the sequence of the active test dose maintaining the progressive increase from lowest to maximum dose (example of blind sequence: 0.5 mg, p, 1 mg, 5 mg, p, 10 mg, p, and 20 mg). The capsules were administered in the morning on an empty stomach, one challenge dose per day (challenge test maximum duration, eight days).
The patients were asked to record the symptoms triggered by each dose, including the time of onset, their intensity, and duration. Patients with positive challenge underwent a medical check-up. The challenge test was regarded as positive when it proved it had caused a relapse or a sudden aggravation of the residual clinical manifestations, with widespread itching and an increase of at least 60% of the skin map score, after the intake of one dose of nickel but not after the administration of the p.
The study was approved by the Local Ethical Committee (approval number 946, 05.10.95), the challenge tests were performed in day-hospital regimen, and written informed consent was obtained from all patients.
RESULTS
Patient Population
According to the criteria listed in the method section, we screened a population of 1726 adult patients, aged 16 -65 years, mean age 36 Ϯ 14 years, 1415 (82%) woman. Study results are summarized in the flowchart shown in Fig. 1 .
Nickel patch test positivity was found in 339 patients, a percentage (19.64%) not different from that found in general population in Europe. 34, 35 A total of 118 of these patients (34.80%) were suffering from chronic urticarious skin manifestations, 96 (28.32%) from scattered chronic pruriginous eczema, 91 (26.84%) from adult atopic-like eczema lesions, and 34 (10.03%) from chronic pruritus.
Cosensitization was seen in 96 cases. Thirty-four patients (33%) to cobalt and 68 to fragrance mix (65%). Eight patient showed cosensitization to balsam of Peru (8%); 41 patents (41%) showed other contact sensitizations, but none potentially related to SCDs. For the patients sensitized to balsam and/or fragrance, avoidance diet 36, 37 was prescribed for four weeks without significant improvement.
Most patients showed no lesions consistent with ACD. More than half of them (183 ϭ 53.98%) neither had nor had ever had a history of contact dermatitis. Of the remaining patients, 84 (24.78%) referred some problems with costume jewelry or had suffered from a mild form of ACD in the past, and only 72 (21.24%) showed an association with some skin lesions possibly related to a contact dermatitis.
None of the patients considered in the present study suffered from relevant extracutaneous symptoms. They should not be included in the so-called Systemic Nickel Allergy Syndrome, which might be a different phenotypic expression of nickel allergy. This definition has been recently coined to describe a clinical condition that links together cutaneous manifestations (such as ACD, pompholyx, erythema, urticaria, angioedema, and dysydrosis), gastrointestinal disorders with mucosa histopathologic changes, and a number of sys- 
Low-Nickel Diet and Challenge Test Results
Fifty-two patients (15.33%) recovered by avoiding the contact with any possible sources of nickel.
Of the patients whose clinical symptoms did not improve by exclusion of nickel contact, 29 (10.10%) dropped out, most of them because of a poor compliance with prescribed diet. The remaining 258 patients (84.66%) accomplished a nickel elimination diet.
Low-nickel diet resulted in a complete or near complete recovery of skin manifestations in 207 patients (80.23%) and proved ineffective only for 51 patients (19.77%).
The DBPCNC proved positive in 185 (89.37%), a number corresponding to 10.72% of the entire population included in the study. Seventy patients (38%) suffered from adult atopic eczema; 54 (29%) from chronic urticarious skin eruptions; 43 (23%) from scattered eczema; and 18 (10%) from generalized pruritus. The distribution of the patients with positive nickel challenge was not significantly different from the starting population by skin clinical manifestations (p ϭ 0.071, not significant).
Negative DBPCNC was observed in 22 patients (10.63%), half of them suffering from chronic pruritus, nine from urticarious skin eruptions, and two from scattered eczema.
Challenge dose ranged from 0.5 to 20 mg, with an average dose of 6.19 Ϯ 5.86 mg. A total of 15 patients (8.11%) reacted to the minimum dose of 0.5 mg and 21 (11.35%) to the maximum dose of 20 mg.
The time of onset of cutaneous manifestations after the challenge ranged about from 3 to12 hours, but it was not always precisely reported because of a gradual beginning and a slow progression of symptoms. Only in the cases in which the effects of the challenge test showed a very rapid evolution of clinical manifestations, the patients were able to report the trigger time more precisely. Anyway, the average time of provocation has been estimated of 5.30 Ϯ 2.45 hours.
No precise correlation was found between dose and severity degree of clinical manifestations induced by the challenge. Obviously, in the cases of weak or dubious result of the previous test dose, the prosecution of the challenge procedure and, as a consequence, the progressive increase of the doses was required to achieve stronger and clearer response. Nevertheless, we were able to observe that, as general criterion, the stronger and prompter the response, the smaller the challenge dose was.
In a number of patients (26/185 ϭ 14.05%), the provocation test induced particularly marked effects, with intense itching, symmetrically spread erythematous or maculo-papular rash, generalized urticarious rash, or baboon syndrome. In all these cases, a severe flare-up of the previous positive nickel patch test was observed.
However, a recall of the previous positive nickel patch test was regularly seen in all patients with a strong reaction to challenge test; seventy-nine patients altogether, with a cumulative frequency of approximately 43% of all positive challenge tests. No patient showed signs of systemic anaphylaxis, shock, or any other serious or life-threatening symptoms, neither relevant provocation of extracutaneous symptoms was seen. During the medical check-up, all cases of positive challenge were treated with betamethasone (4 or 1.5 mg, intramuscular or intravenous, based on severity of skin reactions) and second generation antihistamine per os. A clear improvement of skin manifestation was usually seen within a few hours (two to four hours) and complete disappearance generally not later than 24 hours. However, they were requested to continue therapy orally at home, with antihistamine and corresponding reduced doses of steroid (1 or 2 mg) for the next two days.
DISCUSSION
The results of the present retrospective study confirm that dietary nickel can be the chief trigger for provocation and persistence of symptoms in a subpopulation of patients with chronic allergic-like idiopathic dermatitis syndromes and nickel sensitization. [7] [8] [9] [10] [11] Previous experimental studies in patients with ACD had demonstrated that systemically absorbed nickel can be the real cause for the onset of both secondary eruptions in those where a simple contact exposure cannot account for the distribution or the aggravation of skin lesions and, in some cases, of widespread dermatitis syndromes, which include a variety of clinical manifestations ranged from maculo-papular rash to flexural dermatitis, toxicoderma, and chronic urticaria. 3-6,12-14,16 -20 But still, the relationship between dietary nickel and SCD remains controversial. The studies concerning systemically induced nickel dermatitis have been brought into questions because of some inconsistencies related to diagnostic procedures, diet, and doses of challenge. 41, 42 Indeed, a standardized or shared study protocol does not exist, and the various studies are not comparable because of substantial differences on typology of patients, criteria for selection and inclusion, methods, doses, and challenge procedures.
There is no doubt that, as for any other food allergy or intolerance, the gold standard of a correct diagnosis is based on the results of the elimination diet and of the corresponding, double blind, p-controlled provocation test. Unfortunately, major criticisms concern just the diet and the doses of the challenge.
Nickel appears to be a common contaminant of foods, and its content in the diet can considerably vary according to food habits and the concentration of the metal in the subsoil (from 5 to 500 g/g), which in turn influences the nickel content in specific food, in drinking water (5-100 g/L), and from stainless steel cook utensils. Without going into details, measuring the daily intake by diet is extremely difficult, but an average intake of 0.2-0.6 mg appears to be consistent with results of different sources. 27, 28, [43] [44] [45] Of course, different estimates of nickel content in food can influence the prescription of a low-nickel diet, but there is general agreement that some food (i.e., peanuts, legumes and soybeans, oats, cocoa and chocolate, nuts, grains, whole wheat, and wholemeal flours) are of high-nickel content and constitute the core of a low-nickel content diet. 27, 28 Moreover, great differences in individual sensitivity to nickel and in individual nickel absorption and excretion have been demonstrated. 5,46 -48 In our opinion, all this could be a diagnostic problem only as a cause of false inefficacy of the prescribed diet and, as a consequence, a cause of underestimation of the epidemiologic relevance of the problem.
For practice purposes, when we can verify a good control of the symptoms and the objective recovery or near complete healing of the skin manifestations, variations on nickel content cannot change the clinical judgment on efficacy of the diet, but clearly they can influence the value of the threshold dose on the following DBPCNC.
A pivotal criticism concerns the doses needed to elicit a positive response by challenge test, because in most studies, they exceed up to 10 times the nickel amount deemed present in a normal diet. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] Also in our experience, the average challenge dose was higher than in normal diet but just of a light increase (from 0.78 to 1.38 mg above the maximum and the minimum estimated intake by diet), and at least for a certain number of cases, mainly those with stronger and prompter response to the challenge, the dose proved very small (less than or equal to 0.2 mg).
To explain the difference between challenge dose and average intake by diet, we can suppose that the intake on an empty stomach, in form of nickel-salt (not by food), could influence the absorption and the metabolism of the hapten. 33 In any case, we must consider that the nickel challenge test is very specific, because it proved ineffective in healthy subjects and patient with hand eczema or allergic-like dermatitis syndromes not sensitized to nickel. 8, 32, 33 Moreover, the flare-up reaction of previously positive nickel patch test is an identifying mark of a systemic provocation and is generally accepted as conclusive, firm evidence of the specificity of nickel provocation. 32,49 -51 A recall of previous nickel-positive patch test can occur in varying measure, depending on challenge dose, on the time of previous patch test, and the intensity of cutaneous reaction. 3, 5, 18, 50 In agreement with published data, also in the present study, a strong correlation between the intensity of the cutaneous response and the flare-up of the previous positive nickel patch test was found.
The pathogenesis of the nickel-induced SCD is not clearly defined.
A number of studies show that, after oral nickel challenge, tissue lymphocyte alterations and cytokine profiles are consistent with a T cell-mediated, delayed type IV hypersensitivity reaction. 38, [52] [53] [54] However, in all cases of generalized skin response (i.e., excluding some cases of mere reactivation of localized ACD), there are no reports in literature of positive oral nickel challenge later than 12 hours. In the present study, the trigger times after oral intake almost always ranged between three and seven hours.
Both the times of symptoms provocation after nickel challenge, which are shorter than expected, and the provocation of widespread rash with urticaria are considered little consistent with a classic cell-mediated reaction.
A combined type III and IV immune-reaction has been hypothesized. Old studies had shown in the blood antibodies against hapten-albumin complexes. 55, 56 These experimental studies have not been repeated by other authors, and unfortunately Ig complexes have been demonstrated only in a single case of SCD to mitomycin. 57 Some studies have shown that skin symptoms like urticaria and angioedema could be directly mediated by T cells in some patients for whom the involvement of IgE antibodies had been excluded. 58 In nickel SCD, an IgE-mediated reaction appears highly unlikely. Skin-prick tests resulted negative, and specific IgE against nickel cannot been found in our previous experience on this topic. 8 However, as in other cases of allergic-like reactions, a nonspecific or at least non-IgE-mediated release of inflammation mediators from mast cells and basophiles could be a possible, alternative mechanism. 59 The possible role of mast cells in the pathogenesis of flare-up reactions by nickel challenge has been held by some histologic examinations. 48, 51 And more recent studies on the hapten-induced contact hypersensitivity, which represent the classic model of a T cell-mediated hypersensitivity reaction, show that a strong inflammation response on the skin is elicited well before the activation of nickel-specific T cells. 60, 61 A broad spectrum of chemokines is released, including Regulated on Activation, Normal T cell Expressed and Secreted (RANTES), which can play a fundamental role in histamine and serotonin generation and trigger human mast cell degranulation. [62] [63] [64] Here, we must emphasize the concept that the results of this retrospective study have been derived exclusively from a case series of patients suffering from widespread allergic-like dermatitis, not from ACD. More than half of them neither had nor had ever had a history of contact dermatitis. Most of the remaining patients reported some problems with costume jewelry or had suffered from a mild form of ACD in the past, but only a very small minority of patients showed in association some skin lesions consistent with a contact dermatitis.
We think that the results of the present study, which confirms our previous research on the topic, 8 highlight, in clinical practice, the real importance of nickel sensitization and of dietary nickel for the provocation and persistence of skin lesions in a subpopulation of patient with allergic-like dermatitis syndromes. Limited (our unpublished) data inferred from the follow-up of some patients considered for the present study seem to demonstrate that a prolonged diet period, for about one year, could induce a stable healing. However, in literature there is neither information on the "natural" course of nickel SCDs nor clinical studies on long-term effects of low-nickel diet.
The results of the present study are based on retrospective clinical observations, so in theory they might have some bias. Prospective studies should corroborate and add evidence to these observations.
In conclusion, we believe that in practical, routine clinical work, patients with idiopathic urticaria and other allergic-like, non-IgE-mediated dermatitis syndromes should be patch tested and, if nickel-positive, should go on a low-nickel content diet and if necessary a confirmatory DBPCNC.
